Athira Pharma (United States)

Recent papers from Athira Pharma (United States)

1. Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic FrameworkBiomedical Chromatography · 2026
2. Rodatristat Ethyl Decreases Activity in Pulmonary Arterial Hypertension: Results from the ELEVATE-2 TrialAnnals of the American Thoracic Society · 2026
3. ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzoleFrontiers in Neurology · 2026
4. Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosisBMJ Open Respiratory Research · 2025
5. 3D-Printed Alginate–Chitosan Hydrogel Loaded with Cannabidiol as a Platform for Drug Delivery: Design and Mechanistic CharacterizationJournal of Functional Biomaterials · 2025
6. 3D-Printed Alginate–Chitosan Hydrogel Loaded with Cannabidiol as a Platform for Drug Delivery: Design and Mechanistic CharacterizationJournal of Functional Biomaterials · 2025
7. Fosgonimeton in mild-to-moderate Alzheimer's diseaseJournal of Alzheimer s Disease Reports · 2025
8. Self-replicating recombinant virus-like particles of lentivirus proliferating in glioblastoma cells and normal human macrophagesJournal of microbiology epidemiology immunobiology · 2024
9. Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practiceAlzheimer s & Dementia Translational Research & Clinical Interventions · 2024
10. Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's diseaseAlzheimer s & Dementia Translational Research & Clinical Interventions · 2024
11. Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's diseaseNeurotherapeutics · 2024
12. Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders (P11-4.003)Neurology · 2024
13. ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALSFrontiers in Neuroscience · 2024
14. Survival differences in rheumatoid arthritis interstitial lung disease and idiopathic pulmonary fibrosis may be explained by delays in presentation: results from multivariate analysis in a monocentric UK studyRheumatology International · 2023
15. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trialThorax · 2023
16. The Case for a Novel Therapeutic Approach to Dementia: Small Molecule Hepatocyte Growth Factor (HGF/MET) Positive ModulatorsJournal of Alzheimer s Disease · 2023
17. Development of stable, orally bioavailable small molecule positive modulators of HGF/MET signaling for the treatment of cognitive impairment.Alzheimer s & Dementia · 2022
18. Fosgonimeton, a novel, small molecule positive modulator of the HGF/MET system is neuroprotective in primary neuron cultureAlzheimer s & Dementia · 2022
19. Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related PotentialNeural Plasticity · 2022
20. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical TrialJournal of Alzheimer s Disease · 2022